Sichuan Baili Pharmaceutical Co., Ltd.
98 active trials across 2 therapeutic areas
98
Active Trials
50
Phase 1
45
Phase 2
19
Phase 3
2
Therapeutic Areas
Portfolio Concentration: 122% of active trials in Oncology
Oncology
120 active / 123 total
Solid Tumor (Advanced)
31 active
1 Ph3
32 total since 2015
NSCLC
17 active
5 Ph3
17 total since 2015
Breast Cancer
10 active
1 Ph3
11 total since 2015
Head and Neck Cancer
9 active
9 total since 2015
ALL
6 active
1 Ph3
6 total since 2015
HER2+ Breast Cancer
4 active
3 Ph3
4 total since 2015
Esophageal Cancer
4 active
1 Ph3
4 total since 2015
Gastric Cancer
3 active
1 Ph3
3 total since 2015
Hodgkin Lymphoma
3 active
3 total since 2015
Non-Hodgkin Lymphoma
3 active
3 total since 2015
SCLC
3 active
1 Ph3
3 total since 2015
Bladder Cancer
3 active
1 Ph3
3 total since 2015
Colorectal Cancer
2 active
3 total since 2015
Cervical Cancer
2 active
2 total since 2015
Lung Cancer (General)
2 active
2 total since 2015
Hematologic Malignancies
2 active
2 total since 2015
AML
2 active
1 Ph3
2 total since 2015
Triple Negative Breast Cancer
2 active
1 Ph3
2 total since 2015
Endometrial Cancer
1 active
1 total since 2015
Multiple Myeloma
1 active
1 total since 2015
Brain Tumor
1 active
1 total since 2015
CLL
1 active
1 total since 2015
Neuroendocrine Tumors
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Hepatocellular Carcinoma
1 active
1 total since 2015
Ovarian Cancer
1 active
1 Ph3
1 total since 2015
Cholangiocarcinoma
1 active
1 total since 2015
Squamous Cell Carcinoma
1 active
1 Ph3
1 total since 2015
HER2- Breast Cancer
1 active
1 Ph3
1 total since 2015
Glioblastoma
1 active
1 total since 2015
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)